Companies rushing to adopt AI face hidden costs in “work waste.” The article explores how workflow intelligence tools like Scribe reveal and fix this inefficiency.
As AI funding surges, startups are competing for engineers in public — making hiring their most strategic growth weapon.
From potato-stem cotton substitutes to hemp-based loungewear, a new wave of investors is betting billions on the idea that your clothes should not poison you or the planet.
Women CEOs are closing the pay gap in startups, but ownership still lags—especially in life sciences, where equity determines long-term wealth.
For decades, a blood draw in a clinical lab was the only way to quantify your hormones. In 2026, that paradigm is shifting and we are seeing saliva cartridges analyzed by smartphone AI, DNA-based biosensor patches, earring-back wearables, and sweat sensors are converging to make hormone tracking as routine as measuring heart rate. The market, valued at $325.7 million in 2025 and projected to reach $716.2 million by 2035, is opening up to a broader hormonal health market representing an estimated $600 billion opportunity The filed is now bubbling up with cohorts of academic breakthroughs, deep tech hardware bets, and AI platforms that are changing how we might be measing hormones in years to come.
AI’s 2026 megacycle is concentrating capital, compressing startup growth, reshaping IPO and forcing new monetization models that reward durable, AI native advantages.
Explore how leading VCs build informed judgment, back non-obvious founders, and design cultures that protect outliers turning ambiguity into long-term impact.
Why the biggest VC wins start with discomfort. Learn how conviction beats consensus in venture capital and why great bets can come from the most unexpected places.
How security and governance protocols at family offices are evolving when utilizing “vibe coding” and agentic AI
The longevity industry has reached an inflection point. With companies like Function Health raising hundreds of millions in venture capital, biological age testing has moved from academic curiosity to investable market category. Yet behind the funding headlines lies a more nuanced reality: a field grappling with fundamental questions about accuracy, stability, and clinical utility.